These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 33947964)

  • 1. Correction to: p14
    Ozenne P; Dayde D; Brambilla E; Eymin B; Gazzeri S
    Oncogene; 2021 May; 40(20):3633-3634. PubMed ID: 33947964
    [No Abstract]   [Full Text] [Related]  

  • 2. p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway.
    Ozenne P; Dayde D; Brambilla E; Eymin B; Gazzeri S
    Oncogene; 2013 Feb; 32(8):1050-8. PubMed ID: 22450744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.
    Saito K; Takigawa N; Ohtani N; Iioka H; Tomita Y; Ueda R; Fukuoka J; Kuwahara K; Ichihara E; Kiura K; Kondo E
    Mol Cancer Ther; 2013 Aug; 12(8):1616-28. PubMed ID: 23761220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small-cell lung carcinoma harbouring EGFR T790M mutations.
    Yang K; Chen Y; Zhou J; Ma L; Shan Y; Cheng X; Wang Y; Zhang Z; Ji X; Chen L; Dai H; Zhu B; Li C; Tao Z; Hu X; Yin W
    Br J Pharmacol; 2019 Dec; 176(24):4609-4624. PubMed ID: 31322286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma.
    Schneller D; Machat G; Sousek A; Proell V; van Zijl F; Zulehner G; Huber H; Mair M; Muellner MK; Nijman SM; Eferl R; Moriggl R; Mikulits W
    Hepatology; 2011 Jul; 54(1):164-72. PubMed ID: 21452288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway.
    Tsai MF; Chang TH; Wu SG; Yang HY; Hsu YC; Yang PC; Shih JY
    Sci Rep; 2015 Sep; 5():13574. PubMed ID: 26338423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
    Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
    Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival.
    Dayde D; Guerard M; Perron P; Hatat AS; Barrial C; Eymin B; Gazzeri S
    Oncogene; 2016 Jul; 35(30):3986-94. PubMed ID: 26686095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.
    Tam IY; Leung EL; Tin VP; Chua DT; Sihoe AD; Cheng LC; Chung LP; Wong MP
    Mol Cancer Ther; 2009 Aug; 8(8):2142-51. PubMed ID: 19671738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function.
    Zhou J; Ben S
    Thorac Cancer; 2018 Feb; 9(2):228-233. PubMed ID: 29222872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFR
    Wang Y; Lai H; Fan X; Luo L; Duan F; Jiang Z; Wang Q; Leung ELH; Liu L; Yao X
    Front Pharmacol; 2018; 9():728. PubMed ID: 30038571
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
    Sasaki H; Endo K; Takada M; Kawahara M; Kitahara N; Tanaka H; Okumura M; Matsumura A; Iuchi K; Kawaguchi T; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Oct; 54(1):103-8. PubMed ID: 16890322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved therapeutic effectiveness by combining recombinant p14(ARF) with antisense complementary DNA of EGFR in laryngeal squamous cell carcinoma.
    Liu F; Du J; Xian J; Liu Y; Liu S; Lin Y
    Am J Otolaryngol; 2015; 36(6):763-71. PubMed ID: 26545468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma (LSCC).
    Xian J; Lin Y; Liu Y; Gong P; Liu S
    DNA Cell Biol; 2007 Feb; 26(2):71-9. PubMed ID: 17328665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients.
    Yang SY; Yang TY; Chen KC; Li YJ; Hsu KH; Tsai CR; Chen CY; Hsu CP; Hsia JY; Chuang CY; Tsai YH; Chen KY; Huang MS; Su WC; Chen YM; Hsiung CA; Shen CY; Chang GC; Yang PC; Chen CJ
    Clin Cancer Res; 2011 Apr; 17(8):2149-58. PubMed ID: 21300759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
    J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.